Children's Hospital Colorado, Department of Pediatrics, Section of Allergy/Immunology, University of Colorado School of Medicine, Aurora, Colorado.
Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, New Hampshire; Dartmouth Geisel School of Medicine, Hanover, New Hampshire.
Ann Allergy Asthma Immunol. 2020 Jul;125(1):90-96. doi: 10.1016/j.anai.2020.01.030. Epub 2020 Feb 11.
Shared decision making (SDM) is the process through which patients and their medical provider mutually explore therapy goals, risk/benefit, and treatment options regarding medical care. Decision aids are tools that aid in the process of values clarification and help assess decisional needs and potential decisional conflicts.
To develop and assess acceptability of a decision aid for commercial peanut allergy therapies.
The creation of this decision aid occurred in 3 stages, including a qualitative study to assess decisional needs, development of a draft decision aid through multiple iterations in accordance with international guidelines and decision aid experts, and assessment of decisional acceptability, decisional conflict, and decisional self-efficacy related to using the decision aid.
The decision aid went through 9 iterations, resulting in a 4-page aid with 7 parts, explaining the therapies, key risks and benefits of therapy choices, relative importance of key attributes of the therapies, and a self-check assessment regarding informational adequacy and how to take the next steps. A total of 24 subjects assessed the decision aid, noting it had good acceptability, high decisional self-efficacy (mean score 91.9/100), and low decisional conflict (mean score 20.2/100). Respondents rated the information content as adequate and sufficient and the information regarding the therapy choices as fair and balanced without a clear bias or presenting a "best choice."
We have developed this decision aid as a tool to help caregivers navigate the complexity of decision making for peanut allergy treatment options. The decision aid was noted to have good acceptability, with scores reflective of the instrument enhancing decisional self-efficacy and reducing decisional conflict.
共同决策(SDM)是患者及其医疗提供者共同探讨医疗护理的治疗目标、风险/收益和治疗选择的过程。决策辅助工具是帮助澄清价值观、帮助评估决策需求和潜在决策冲突的工具。
开发并评估一种用于商业花生过敏治疗的决策辅助工具的可接受性。
该决策辅助工具的创建分为 3 个阶段,包括一项定性研究,以评估决策需求,根据国际指南和决策辅助专家的意见,通过多次迭代开发一份草案决策辅助工具,以及评估与使用决策辅助工具相关的决策可接受性、决策冲突和决策自我效能感。
该决策辅助工具经过 9 次迭代,最终形成一个 4 页的辅助工具,共 7 个部分,解释治疗方法、治疗选择的关键风险和收益、治疗方法关键属性的相对重要性以及关于信息充分性和如何采取下一步措施的自我评估。共有 24 名受试者评估了决策辅助工具,认为其具有良好的可接受性、高决策自我效能感(平均得分为 91.9/100)和低决策冲突(平均得分为 20.2/100)。受访者认为信息内容充分、足够,关于治疗选择的信息公平、平衡,没有明显的偏见或呈现“最佳选择”。
我们开发了这个决策辅助工具,作为帮助照顾者应对花生过敏治疗选择决策复杂性的工具。该决策辅助工具具有良好的可接受性,其得分反映了该工具增强决策自我效能感和降低决策冲突的作用。